Objective: Evaluate the clinical value of using MANAGE-PD tool for assessing PD symptom control in real-world setting.
Background: MANAGE-PD is a validated [1], web-based tool (https://managepd.com/) designed to support healthcare providers in identifying patients with PD that may be inadequately controlled on oral medications.
Method: A secondary analysis from multi-country Adelphi Parkinson’s Disease Specific Programme was conducted. Device-aided therapy (DAT)-naïve PD patients from G7 countries who were on orals therapy only and managed by movement disorder specialists were included. Based on MANAGE-PD and clinician judgement, patients were independently grouped into 3 categories: (i) adequately controlled on oral therapy; (ii) inadequately controlled on oral therapy and consider oral optimization only, (iii) inadequately controlled on oral therapy and consider evaluation for DAT along with oral optimization. Concordance between the two assigned categories was evaluated. Amongst the discordant cases, accuracy was assessed based on comparing known measures of higher disease severity between patients scored as higher severity by MANAGE-PD and higher severity by clinician judgement.
Results: Of the analytical sample, 858 (43%) patients had mismatch in level of clinical control between MANAGE-PD and clinical judgement [Table 1]. Among mismatched cases, there was an almost equal distribution of patients rated as higher severity by MANAGE-PD (n=440) and patients rated as higher severity by clinician judgement (n=418) [Table 1]. Comparing these two groups, patients rated as higher severity by MANAGE-PD tool were observed to have: (i) ~2x higher average daily of off-time (1.6±2.1 hrs vs 0.9±1.9 hrs, p<0.01), (ii) ~2x higher hospitalization rate (16% vs 8%, p<0.01), (iii) ~1.5x higher average weekly caregiver use (35.4±45.2 hrs vs 21.4±43.4 hrs, p<0.01), (iv) significantly poorer quality of life (PDQ-39 index score 35.2±18.3 vs 26.6±16.8, p<0.01), and (v) significantly higher caregiver burden (ZBI score 33.6±17.9 vs 23.8±18.6, p<0.01).
Conclusion: Amongst the discordant cases, patients rated as having higher severity on MANAGE-PD also demonstrated higher disease burden. Clinical use of MANAGE-PD tool may facilitate timely identification and management of symptoms, and possibly improving PD patients’ quality of life.
References: 1. Antonini A, Odin P, Jalundhwala Y, Schmidt P, Skalicky A, Kleinman L, Zamudio J, Onuk K, Kukreja P, Bao Y, Cubillos F, Fernandez H. Assessing the validity and reliability of MANAGE-PD tool to identify patients with Parkinson’s disease inadequately controlled on oral medications – Results from an international survey of general neurologists and movement disorder specialists [abstract]. Mov Disord. 2019; 34 (suppl 2).
To cite this abstract in AMA style:
A. Antonini, P. Odin, A. Alobaidi, F. Cubillos, P. Schmidt, Y. Jalundhwala, K. Onuk, J. Zamudio, P. Kukreja, E. Jones, J. Wright, H. Fernandez. Demonstrating the clinical value of MANAGE-PD tool in assessing symptom control of Parkinson’s disease patients: Evidence from G7 countries [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/demonstrating-the-clinical-value-of-manage-pd-tool-in-assessing-symptom-control-of-parkinsons-disease-patients-evidence-from-g7-countries/. Accessed November 22, 2024.« Back to MDS Virtual Congress 2020
MDS Abstracts - https://www.mdsabstracts.org/abstract/demonstrating-the-clinical-value-of-manage-pd-tool-in-assessing-symptom-control-of-parkinsons-disease-patients-evidence-from-g7-countries/